Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia by Kim, Shin-Young et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Medical Genetics
Open Access Research article
Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 
(Flt-1) gene is not associated with preeclampsia
Shin-Young Kim1, Ji-Hyae Lim1, Jae-Hyug Yang2, Moon-Young Kim2, Jung-
Yeol Han2, Hyun-Kyong Ahn2, Jun-Seek Choi2, So-Yeon Park1, Mi-Jin Kim1 
and Hyun-Mee Ryu*1,2
Address: 1Laboratory of Medical Genetics, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine, 
Seoul, Korea and 2Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University 
College of Medicine, Seoul, Korea
Email: Shin-Young Kim - chlorella@empal.com; Ji-Hyae Lim - roollala@hanmail.net; Jae-Hyug Yang - jhy60408@yahoo.co.kr; Moon-
Young Kim - mykimdr@yahoo.co.kr; Jung-Yeol Han - hanjungyeol@yahoo.com; Hyun-Kyong Ahn - hkahn@yahoo.com; Jun-
Seek Choi - dj9036@hanmail.net; So-Yeon Park - paranip@yahoo.co.kr; Mi-Jin Kim - bluemint99@nate.com; Hyun-
Mee Ryu* - hmryu@yahoo.com
* Corresponding author    
Abstract
Background: Preeclampsia is a major cause of maternal and perinatal mortality and morbidity. The etiology of
preeclampsia remains unclear. Recently, it was shown that misregulation of fms-like tyrosine kinase-1 (Flt-1) in
the peripheral blood mononuclear cells of pregnant women results in over-expression of the soluble splice variant
of Flt-1, sFlt-1, producing an additional (extra-placental) source of sFlt-1 that can contribute to the etiology of
preeclampsia. The aim of this study was to investigate the relationship between preeclampsia and a dinucleotide
(threonine-glycine; TG)n repeat polymorphism in the 3' non-coding region of the Flt-1 gene.
Methods: The number of the d(TG)n repeats was analyzed in 170 patients with preeclampsia and in 202
normotensive pregnancies. The region containing the dinucleotide repeat polymorphism of the Flt-1 gene was
amplified by polymerase chain reaction (PCR) from the DNA samples and was analyzed by direct PCR sequencing.
Results: We found 10 alleles of the dinucleotide repeat polymorphism and designated these as allele*12 (A1)
through allele*23 (A12) according to the number of the TG repeats, from 12 to 23. The frequency of the 14-
repeat allele (A3) was most abundant (63.82% in preeclampsia and 69.06% in controls), followed by the 21-repeat
allele (A10; 28.53% in preeclampsia and 23.76% in controls). There was no significant difference in the allele
frequency between patients with preeclampsia and normal controls. The most common genotype in preeclamptic
and normotensive pregnancies was heterozygous (TG)14/(TG)21  (41.76%) and homozygous (TG)14/(TG)14
(45.05%), respectively. However, the genotype frequencies were not significantly different between preeclamptic
patients and controls.
Conclusion: This is the first study to characterize the dinucleotide repeat polymorphism of the Flt-1 gene in
patients with preeclampsia. We found no differences in the allele or genotype frequencies between patients with
preeclampsia and normal pregnancies. Although limited by a relatively small sample size, our study suggests that
the d(TG)n repeat polymorphism of the Flt-1 gene is not associated with the development of preeclampsia in
Korean pregnant women.
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Background
Preeclampsia, a pregnancy-specific syndrome affecting
about 5% to 10% of all pregnancies, is characterized by
hypertension and proteinuria after 20 weeks of gestation.
It is a major cause of maternal and perinatal morbidity
and mortality and occurs only in the presence of a pla-
centa and remits dramatically after the placenta has been
delivered. The underlying pathogenetic mechanisms of
this maternal syndrome are much debated with the cur-
rent hypotheses including inflammatory disease, vascular-
mediated factors, placental ischemia, genetic predisposi-
tion and immune maladaptation [1-3]. Preeclampsia is
also associated with defective uteroplacental vasculariza-
tion [4] and impairment of angiogenesis and vascular
transformation of the uteroplacental unit, which are cru-
cial for normal fetal development [5]. However, the
molecular pathways responsible for normal angiogenesis
and vascular remodeling in the fetomaternal unit are still
poorly understood.
Vascular endothelial growth factor (VEGF) is a major ang-
iogenic factor and plays an important role in all aspects of
vascular development, including endothelial cell prolifer-
ation, migration, survival and regulation of vascular per-
meability [6,7]. VEGF and its two receptors, fms-like
tyrosine kinase 1 (Flt-1) (VEGFR-1) and KDR/Flk-1
(VEGFR-2), have been shown to be part of an essential
regulatory system for blood vessel formation. One of the
two receptors, Flt-1 appears to have dual functions, with
negative and positive activity in vascular endothelial cells.
In early embryogenesis, Flt-1 functions as a negative regu-
lator, most likely through its strong VEGF trapping activity
[8]. Flt-1 (-/-) mice are embryonic lethal due to the disor-
ganization of blood vessels and overgrowth of endothe-
lial-like cells within the lumens of blood vessels [9]. In
adult stages, however, Flt-1-specific ligand can induce a
mild angiogenesis. Thus, this dual function may be tightly
regulated and important for fine tuning the formation
and maintenance of the blood vessel structure in placental
vasculature.
During placental development, the expression of the Flt-1
gene is not only detected in vascular endothelial cells, but
also in the developing trophoblasts [10]. The Flt-1 gene is
located in the chromosome region 13q12 and consists of
30 exons and 29 introns [11,12]. The gene encodes a high
affinity receptor for VEGF, which has sixth immunoglob-
ulin (Ig)-like domains in the extracellular region based on
the distribution of cysteine residues, a transmembrane
domain and an intracellular region containing a tyrosine
kinase domain divided by a long kinase-insert domain
[11,13]. There is a dinucleotide repeat in the 3' non-cod-
ing region of the Flt-1 gene [11] that has been shown to be
polymorphic [14,15]. This region of the gene codes for the
intracellular part of the protein that is likely associated
with signal transduction. Dinucleotide repeat regions are
often used as disease markers and their functional signifi-
cance is being increasingly realized [16,17]. Considering
the important roles of Flt-1 in pregnancy, functional pol-
ymorphisms in the Flt-1 gene may be potentially impor-
tant as genetic markers for susceptibility to preeclampsia.
Based on genetic predisposition, this relationship may be
strengthened by showing an association between poly-
morphisms of Flt-1 gene and an increased risk of develop-
ing preeclampsia. In view of the possible role of the Flt-1
gene in the etiology of preeclampsia, we investigated
whether the dinucleotide (threonine-glycine; TG)n repeat
polymorphism in the 3' non-coding region of the Flt-1
gene is associated with preeclampsia in Korean pregnant
women.
Methods
Subjects
All subjects were recruited from the Obstetrics and Gyne-
cology Department at Cheil General Hospital between
October 2001 and June 2004. The study population
included 170 patients with preeclampsia (13 mild and
157 severe) and 202 sampling week-matched normal
pregnancies of Korean origin. Preeclampsia was defined as
hypertension (systolic blood pressure ≥ 140 mmHg and/
or diastolic blood pressure ≥ 90 mmHg after 20 weeks'
gestation) and proteinuria (≥ 300 mg in a 24 h urine col-
lection or ≥ 1+ on dipstick testing) according to the crite-
ria of the National High Blood Pressure Education
Program Working Group Report on High Blood Pressure
in Pregnancy [18]. Severe preeclampsia was diagnosed on
the basis of diastolic blood pressure ≥ 110 mmHg or sig-
nificant proteinuria (dipstick measurement of ≥ 2+) or the
presence of headache, visual disturbances, upper abdom-
inal pain, oliguria, convulsion, elevated serum creatinine,
thrombocytopenia, marked liver enzyme elevation or pul-
monary edema [18]. Only one woman was a HELLP syn-
drome in preeclamptic patients. Exclusion criteria
included major congenital anomalies, fetal chromosomal
abnormalities, chronic hypertension, diabetes or renal
disease. Controls were selected randomly from contem-
poraneous women who were normotensive and who were
without proteinuria throughout pregnancy, and who
delivered a healthy neonate at term without significant
medical or obstetric complications (including intrauter-
ine growth retardation; IUGR). IUGR was defined as a
birth weight less than the 10th percentile for gestational
age. Written informed consent was obtained from all sub-
jects before blood sampling, which was approved by the
Ethics Committee of Cheil General Hospital and
Women's Health Care Center.
DNA Sequencing
Peripheral blood was collected in EDTA vacutainer tube
(Becton Dickinson, USA) for genomic DNA isolation.BMC Medical Genetics 2008, 9:68 http://www.biomedcentral.com/1471-2350/9/68
Page 3 of 6
(page number not for citation purposes)
Genomic DNA was extracted from whole blood using a
QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden
Germany) according to the manufacturer's recommenda-
tions. A genomic fragment containing the d(TG)n repeat
polymorphism of the Flt-1 gene was amplified by
polymerase chain reaction (PCR) using the fluorescent
6FAM-labelled forward primer 5'-6FAM-TTT-
GGCCGACAGTGGTGTA-3' and the unlabelled reverse
primer 5'-CTTTAAAATTCCAGTTTCCTT-3', according to
Parry [19]. PCR reactions were performed in a final vol-
ume of 20 ul containing 10 ng of genomic DNA, 2 ul of
10× PCR buffer (Applied Biosystems, Foster City, CA,
USA), 1.25 mM MgCl2 (Applied Biosystems), 1 mM of
each dNTP (Applied Biosystems), 10 pmol of each specific
primer and 1 U of Taq DNA Polymerase (Applied Biosys-
tems). The PCR conditions consisted of an initial denatur-
ation at 95°C for 5 min, followed by 33 cycles of
denaturation at 95°C for 40 s, annealing at 55°C for 40 s,
extension at 72°C for 40 s, and a final extension at 60°C
for 30 min on ABI PRISM 2700 thermal cycler (Applied
Biosystems). An aliquot of the amplified PCR product was
electrophoresed on a 3% neusive gel to verify product
quality and quantity.
PCR products were purified with AccuPrep® PCR purifica-
tion kit (BIONEER, Korea) and the purified PCR products
were sequenced with an ABI PRISM BigDye Terminator
Cycle Sequencing Kit (Applied Biosystems). The number
of TG repeats within each allele was analyzed by direct
sequencing using an ABI PRISM 3100 Genetic Analyzer
(Applied Biosystems). The electropherogram traces were
interpreted by Genescan software version 3.7 (Applied
Biosystems) and corresponding genotypes assigned using
Genotyper software version 3.7 (Applied Biosystems). All
samples were analyzed twice to confirm the integrity of
the results.
Statistical Analysis
Data were expressed as the mean ± SD, median (range) or
number (%). The Student's t-test was used for comparison
of continuous variables between normal controls and
preeclamptic patients. Categorical variables, such as the
comparison in the allele and genotype frequencies
between the two groups, were analyzed by a 2 × 2 Chi-
Squared test or Fisher's exact test. Odds ratios (OR) and
95% confidence intervals (CI) were calculated to assess
the disease risk conferred by genotypes. Hardy-Weinberg
equilibrium was tested in patients 0.05 was considered
statistically significant. and controls, separately, by means
of the Chi-Squared analysis http://www.fourmilab.ch/
rpkp/experiments/analysis/chiCalc.html. A p value < 0.05
was considered statistically significant. The statistical
analysis was performed with the Statistical Package for
Social Sciences version 10.0 (SPSS Inc., Chicago, USA).
Results
Polymorphism analysis of the Flt-1 gene was performed
for 170 preeclamptic patients and 202 normotensive preg-
nancies. The clinical characteristics of the study popula-
tion are shown in Table 1. Maternal age, nulliparity, blood
pressure, maternal weight at delivery, gestational age at
delivery and birth weight were found to be significantly
different between the two groups (p < 0.05). In addition,
58 (34.12%) of the 170 preeclamptic patients delivered a
fetus with IUGR, defined as birth weight below the 10th
percentile for gestational age.
Ten alleles observed in this study groups were designated
as allele*12 (A1) through allele*23 (A12), according to
the number of TG repeats, which ranged in size from 102
bp (12 TG repeats with a 78 bp segment of amplified
flanging sequences) to 124 bp (23 TG repeats) (Table 2).
The frequency of the 14-repeat allele (A3) was most abun-
dant (63.82% in preeclampsia and 69.06% in controls),
followed by the 21-repeat allele (A10; 28.53% in preec-
lampsia and 23.76% in controls) (Table 2). The allele fre-
Table 1: Clinical characteristics of normal controls and preeclamptic patients
Characteristics Controls
(n = 202)
Patients
(n = 170)
p value*
Maternal age (y) 32.8 ± 3.7 30.9 ± 3.8 < 0.001
Nulliparity (%) 94 (46.5) 139 (81.8) < 0.001†
Systolic BP (mmHg) 121.8 ± 10.2 159.2 ± 16.6 < 0.001
Diastolic BP (mmHg) 75.3 ± 8.7 100.5 ± 11.8 < 0.001
Maternal weight at delivery (kg) 68.0 ± 7.8 74.2 ± 10.3 < 0.001
GA at delivery (wk) 39.1 ± 1.3 36.5 ± 3.3 < 0.001
Birth weight (g) 3356.9 ± 436.1 2528.0 ± 776.4 < 0.001
Proteinuria (dipstick) - 2.6 ± 1.0 -
IUGR (number) - 58 -
BP = blood pressure; GA = gestational age; IUGR = intrauterine growth retardation
A p value was calculated using the *Student's t-test or †Chi-Squared test.
Significant value was taken at the level of p < 0.05.BMC Medical Genetics 2008, 9:68 http://www.biomedcentral.com/1471-2350/9/68
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quency was very similar to that previously reported for an
American population [14]. Interestingly, the 12-, 15-, 19-
, and 20-repeat alleles had not previously been reported.
However, the allele frequencies of the Flt-1 (TG)n poly-
morphism in patients with preeclampsia did not differ
from those in normal controls. Furthermore, the genotype
frequencies in preeclampsia and controls did not signifi-
cantly deviate from Hardy-Weinberg equilibrium (data
not shown). The genotypes were classified into five
groups; (TG)14/(TG)14, (TG)14/(TG)21, (TG)21/(TG)21,
Other, Combination (Table 3). The most common geno-
type in normal controls (45.05%) was homozygous
(TG)14/(TG)14, whereas those in preeclamptic patients
(41.76%) was heterozygous (TG)14/(TG)21 (Table 3). We
compared each reference group [(TG)14/(TG)14, (TG)14/
(TG)21, or (TG)21/(TG)21 genotype] with Other (Table 3).
Additionally, we also compared (TG)14/(TG)14 genotype
with the combined genotype [(TG)14/(TG)21+(TG)21/
(TG)21+Other] (Table 3). However, the genotype frequen-
cies of the Flt-1 (TG)n polymorphism in preeclamptic
patients did not differ from those in normotensive preg-
nancies.
Discussion
Microsatellites are powerful tools for performing linkage
and association studies for diseases but they may also be
directly involved in the modification of gene expression
levels by silencing/enhancing transcription and modulat-
ing splicing events [20,21]. Since the microsatellite is
located within intronic sequence with no obvious func-
tional relevance, as shown by Turecki [22], it is possible
that specific alleles of this repeat may be in linkage dise-
quilibrium with a nearby polymorphism that affects dis-
ease susceptibility. Moreover, variability in simple
intronic repeats is probably involved in the etiology and
pathogenesis of multifactorial diseases [23].
However, although genetic factors have been extensively
investigated during the past decade [24], the dissection of
the genetic basis for preeclampsia has been challenged by
the wide clinical heterogeneity of this disorder and the
lack of a full understanding of its underlying cause. The
genes expressed in the placental vasculature throughout
pregnancy are attractive candidate genes and nearly all
accessible genes have been extensively analyzed. The Flt-1,
a major receptor for VEGF, is produced as a 1338 amino
acid residue precursor with a predicted 22 amino acid sig-
nal peptide. The extracellular domain of Flt-1 is composed
of 736 amino acids; its transmembrane spanning domain
is 22 amino acids and its intracellular domain is 558
amino acids. Spongiotrophoblast cells, endothelial cells
and their progenitors are the major placental source of Flt-
1 [25,26]. Given the regulatory role of Flt-1 in pregnancy
and the presence of a multiallelic polymorphism in the
Flt-1 gene, Flt-1 could conceivably be a candidate suscep-
tibility gene in preeclampsia.
In this study, we focused on a d(TG)n repeat polymor-
phism in the Flt-1 gene which may be associated with
preeclampsia in Korean pregnant women. First, the Flt-1
gene contains a polymorphic TG dinucleotide repeat in
the 3' non-coding region that might affect signal transduc-
tion. Secondly, decreased Flt-1 expression has been shown
in the placental bed of preeclamptic patients [27]. The
down-regulation of Flt-1 in the placental bed may result
in a decreased maternal vascular adaptation to pregnancy
[27]. Third, the production of the soluble, alternatively
spliced Flt-1, sFlt-1, is significantly higher in preeclamptic
patients compared with normotensive pregnant women
Table 2: Allele frequencies of the Flt-1 (TG)n polymorphism in 
normal controls and preeclamptic patients
Allele TG repeat Controls Patients
(PCR product length, bp) 2n (%) 2n (%)
A1 12 (102) 2 (0.50) 0 (0.00)
A2 13 (104) 4 (0.99) 4 (1.18)
A3 14 (106) 279 (69.06) 217 (63.82)
A4 15 (108) 3 (0.74) 2 (0.59)
A5 16 (110) 1 (0.25) 0 (0.00)
A6 17 (112) 0 (0.00) 0 (0.00)
A7 18 (114) 0 (0.00) 0 (0.00)
A8 19 (116) 5 (1.24) 3 (0.88)
A9 20 (118) 2 (0.50) 6 (1.76)
A10 21 (120) 96 (23.76) 97 (28.53)
A11 22 (122) 8 (1.98) 7 (2.06)
A12 23 (124) 4 (0.99) 4 (1.18)
Table 3: Genotype frequency of the Flt-1 (TG)n polymorphism in 
normal controls and preeclamptic patients
Genotype Controls Patients OR (95% CI) p value
n (%) n (%)
(TG)14/(TG)14 91 (45.05) 65 (38.24) 1.11 (0.59–2.09) 0.746a
(TG)14/(TG)21 76 (37.62) 71 (41.76) 0.85 (0.45–1.60) 0.613b
(TG)21/(TG)21 6 (2.97) 11 (6.47) 0.43 (0.14–1.35) 0.143c
Other 29 (14.36) 23 (13.53) - -
Combination 111 (54.95) 105 (61.77) 1.32 (0.87–2.01) 0.185d
OR = odds ratios; CI = confidence interval.
Other, any genotypes other than the (TG)14/(TG)14, (TG)14/(TG)21, or 
(TG)21/(TG)21 genotype.
Combination, combined genotype [(TG)14/(TG)21+(TG)21/
(TG)21+Other].
A p value was calculated using the Chi-Squared test or Fisher's exact 
test.
Significant value was taken at the level of p < 0.05.
a(TG)14/(TG)14 versus Other.
b(TG)14/(TG)21 versus Other.
c(TG)21/(TG)21 versus Other.
d(TG)14/(TG)14 versus Combination.BMC Medical Genetics 2008, 9:68 http://www.biomedcentral.com/1471-2350/9/68
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[28]. Finally, the embryos of Flt-1 mutant mice develop
vasculature through endothelial cell differentiation. This
vasculature is highly abnormal and unorganized with an
overgrowth of endothelial cells crowding the lumen [29].
Polymeropoulos [14] first demonstrated that a higher per-
centage of 50 individuals from an American population
had the 14-repeat allele of the (TG)n polymorphism in the
3' non-coding region of the Flt-1 gene. They also observed
that the distribution of the (TG)n repeat alleles was bimo-
dal, with two peaks at 14 repeats and 21 repeats, respec-
tively. In this study, we tested, for the first time, the
association between preeclampsia and the TG dinucle-
otide repeat polymorphism in the 3' non-coding region of
the Flt-1 gene. Our data reveals that two alleles (14-repeat
and 21-repeat) predominate in both preeclamptic and
normal pregnancies, similar to the observation of Polyme-
ropoulos [14]. However, we could not find any differ-
ences in the allele or genotype frequencies of Flt-1
between preeclamptic patients and normal controls. This
polymorphism of the Flt-1 gene was also studied by Parry
et al. in minimal change nephropathy (MCN) patients
compared to the standard American population [19]. The
investigators hypothesized that misregulation of Flt-1
may provide a mechanism for the development of proten-
uria in MCN, thus, polymorphisms in this gene may pre-
dispose to MNC. However, they did not demonstrate any
deviation in the allele frequency in patients with MNC,
implying that this locus does not contribute to suscepti-
bility to MCN. Furthermore, we found that this dinucle-
otide polymorphism is not associated with a
predisposition to preeclampsia. Alternatively, the pene-
trance of the Flt-1 gene may be modified by other factors,
including distinct genetic loci that impart susceptibility.
Flt-1 can be activated by VEGF and placental growth factor
(PlGF), which are highly expressed in the placenta. Most
of the Flt-1 produced in the mouse and human placenta
during later stages of gestation is the soluble form (sFlt-1)
generated by alternative splicing of Flt-1, leading to a pre-
mature termination after the sixth Ig-like domain [30].
sFlt-1 binds both VEGF and PlGF and acts as a soluble
antagonist of their action. Flt-1 misregulation in periph-
eral blood mononuclear cells of pregnant women can
result in the over-expression of sFlt-1, which may produce
an additional (extra-placental) source of sFlt-1 that con-
tributes to the etiology of preeclampsia [31]. A recent
report showed that levels of maternal sFlt-1 were elevated
in preeclampsia and that administration of sFlt-1 to preg-
nant rats can cause symptoms of preeclampsia with
glomerular endotheliosis [32]. This idea clearly suggests
that placental Flt-1 can play roles in regulating maternal
vasculature during pregnancy. We have previously shown
that sFlt-1 levels in the second trimester maternal plasma
are significantly higher in women with preeclampsia than
in normal pregnant women [33]; however, we were una-
ble to demonstrate an association between the d(TG)n
polymorphism in the 3' non-coding region of the Flt-1
gene and sFlt-1 levels. 
Most common genetic disorders, such as preeclampsia,
follow a complex mode of inheritance and may result
from variants of many genes, each contributing only a
weak effect to the disease. Common genetic polymor-
phism may explain a portion of the heritable risk for com-
mon diseases. Consequently considerable effort should
be devoted to finding and typing common microsatellite
polymorphisms in the human genome in order to under-
stand the occurrence of relatively common phenotypes.
As trophoblast cells, which also express Flt-1, are fetal of
origin, the role of fetal Flt-1 (TG)n polymorphism needs
also to be examined in the risk of preeclampsia. Although
we do not deny that one of the possible limitations of this
case-control study is the relatively small sample size, we
did take into account several issues that could lead to a
false conclusion, such as established criteria for the diag-
nosis in order to exclude subphenotypes known to differ
in the evaluation of the disease [34] and matching of cases
and controls for several risk factors and for genetic back-
ground.
Conclusion
To our knowledge, this is the first study investigating the
association between the d(TG)n repeat polymorphism in
the 3' non-coding region of the human Flt-1 gene
[14,15,19] and preeclampsia. In the present study, allele
and genotype frequencies of this dinucleotide repeat pol-
ymorphism were not different between preeclamptic and
normal pregnancies. Our results suggest that the Flt-1
(TG)n polymorphism is not associated with susceptibility
to the development of preeclampsia in Korean pregnant
women. This result might be indicative of the large diver-
sity in the genetic background of preeclampsia, although
this observation deserves further analysis in a larger group
of preeclamptic patients.
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